OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.
City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...
4D Molecular Therapeutics (4DMT) released positive topline interim data from Part 1 of the SPECTRA clinical trial. This trial is designed to evaluate 4D-150 in diabetic macular edema (DME) and ...
Australian researchers have identified an association between nocturnal hypoxia and neovascular age-related degeneration (nAMD). 1 Acting on this realization could prevent nAMD in some patients, ...
In a press release, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced it would partner with Klinge Biopharma GmbH and Formycon AG in ...
A research team from Great Britain identified factors, such as mental health issues, lack of diabetic eye screening awareness, and transport difficulties, that interfere with attendance at annual ...
4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.
Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...